Prenetics Global Limited
——
Mentions · 7d total · 14d trend
13
X counts updated 17h ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $PRE, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $PRE.
Medical - Diagnostics & Research
Diagnostic testing volumes are normalizing post-COVID elevated baseline; liquid biopsy and genomic sequencing are the structural growth areas. Reimbursement rate changes (CMS updates) are the primary margin risk for established lab businesses.
Industry benchmark
15-name peer basket
+11.9%YTD
+47.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-6.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-42.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-35.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-7.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
3.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-49.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
62.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 18, 2026$-0.53$-0.84+36.9%
Q1 2026Jun 10, 2026$-1.36$-0.49-177.6%
Q4 2025Feb 18, 2026$-1.75$-0.41-326.8%
Q3 2025Nov 10, 2025$-0.41$-0.55+25.5%
Next earningsMon, Nov 9·consensus EPS $-0.73
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$46.5M+162.9%65.0%-47.1%$-0.52$0
Q1 FY26$36.0M+107.7%64.8%-27.0%$-1.36$-12.1M
Q4 FY25$36.6M+248.6%59.5%-33.9%$-1.75$-22.0M
Q3 FY25$23.6M+202.8%59.5%-26.2%$-0.53$0
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$223.3M$220.3M – $225.8M-$3.46-$4.11 – -$2.525
FY27$407.9M$397.1M – $414.3M-$1.73-$6.63 – $2.242
FY28$546.1M$529.0M – $566.9M-$0.04-$3.63 – $3.773
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+26.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+38.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 12.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.255-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter ResultsPrenetics Global: Marketing Mastery The Key To Robust Revenue GrowthPrenetics Global Limited (PRE) Q2 2026 Earnings Call TranscriptPrenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year PartnershipPrenetics Global Q2 Earnings Call Highlights
More in Medical - Diagnostics & Research
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $PRE on X in the last 7 days.